NYR
NYRADA CDI FORUS [NYR]
Healthcare · ASX Small Cap
$0.5370 -3.2%
Updated 26 Mar 2026 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +0First seen: 2026-02-25
Score Breakdown
Technical56
Catalyst53
Sentiment50
Fundamental38
Momentum71
Risk Gate42
Get alerts when NYR's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- MACD momentum is picking up steam
- Watch out — volume is flowing out even as price holds up. Distribution pattern
- Low cash runway (4 quarters) - dilution risk
- Very high P/S ratio (56.6x)
- CANSLIM S: Tight float (44%)
- Sentiment is mixed — no strong consensus either way
- Strong long-term momentum — up 303% over the past year (excluding last month)
- Excellent risk-adjusted returns — Sharpe of 1.8 means strong gains without wild swings
- Altman Z-Score distress zone (1.70 < 1.81, low-confidence approx)
- RBA hiking (-3pts)
Risk Signals
- Below the 200-day average — the long-term trend is still working against it
- Piotroski F-Score weak (3/9, low-confidence approx)
- Deeply negative margins (-234%)
- Not enough chatter to gauge sentiment — defaulting to neutral
- The bigger volume days are the down days — volume-weighted momentum is negative (-2.09%/day)
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NYR
3 free messages/day · Unlimited with Pro
Recent Catalysts
LOW Presentation - ASX SMIDCaps Conference
MEDIUM Nyrada PROTECT-MI Phase IIa Trial To Commence
NONE Change of Director's Interest Notice - JM
NONE Director Options Issue
NONE Change of Director's Interest Notice - RW
Recent ASX Announcements
| 2026-03-19 | Presentation - ASX SMIDCaps Conference |
| 2026-03-18 | Nyrada PROTECT-MI Phase IIa Trial To Commence |
| 2026-03-09 | Change of Director's Interest Notice - JM |
| 2026-02-20 | Director Options Issue |
| 2026-02-20 | Change of Director's Interest Notice - RW |
Key Metrics
$134.7M
Market Cap
516K
Avg Volume
0.6x
Vol Ratio
$0.09 — $1.44
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-71.0%
ROE
-234.3%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 44% |
| L | Leader vs Laggard | laggard | RS: -12 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #19 of 117 · Sector avg: 46
View all Healthcare signals →Track NYR and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required